AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1508840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0
Study 1508840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) + Lorazepam (1 mg)
Number of subjects: 0
Study 1508840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0
Study 1508840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 0
Study 1508840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6685963 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study 6685963 — intervention group
Group type: EXPERIMENTAL
Intervention: l-amphetamine
Number of subjects: 12
Study 6685963 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31746766 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive mobile phone app (SMART 5-A-DAY)
Number of subjects: 94
Study 31746766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 94
Study 29957370 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ADs)
Number of subjects: 263
Study 29957370 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 263
Study 27565921 — intervention group
Group type: EXPERIMENTAL
Intervention: E300 (300 mg erlotinib)
Number of subjects: 313
Study 27565921 — intervention group
Group type: COMPARATOR
Intervention: E150 (150 mg erlotinib)
Number of subjects: 313
Study 24635528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and magnesium (Gr K + Mg)
Number of subjects: 50
Study 24635528 — intervention group
Group type: COMPARATOR
Intervention: Ketamine alone (Gr K)
Number of subjects: 50
Study 21725826 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (ER) received 670 nm gallium‐aluminum‐arsenide light-emitting diode device for 80 s at 50 mW/cm² energy density and power exposure of 4 J/cm².
Number of subjects: 80
Study 21725826 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PR) received identical device but <5 mW/cm² energy density.
Number of subjects: 80
Study 19175450 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged detection interval of 30/40 seconds for life threatening ventricular tachyarrhythmia (VT)
Number of subjects: 0
Study 19175450 — intervention group
Group type: COMPARATOR
Intervention: Standard detection interval of 18/24 seconds for life threatening ventricular tachyarrhythmia (VT)
Number of subjects: 0
Study 17939076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary splints (n=35)
Number of subjects: 68
Study 17939076 — intervention group
Group type: COMPARATOR
Intervention: Figure of eight dressing (n=33)
Number of subjects: 68
Study 15482081 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoenix Academy treatment
Number of subjects: 449
Study 15482081 — intervention group
Group type: COMPARATOR
Intervention: Alternative probation disposition
Number of subjects: 449
Study 12575390 — intervention group
Group type: EXPERIMENTAL
Intervention: Qihuang oral liquid (QHOL)
Number of subjects: 70
Study 12575390 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 9653824 — intervention group
Group type: EXPERIMENTAL
Intervention: External drainage
Number of subjects: 0
Study 9653824 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 8171952 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg.kg‐1 intravenously)
Number of subjects: 30
Study 8171952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 3048224 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 1 mg/h
Number of subjects: 12
Study 3048224 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 2 mg/h
Number of subjects: 12
Study 3048224 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 4 mg/h
Number of subjects: 12
Study 3048224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30905173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 8 weeks)
Number of subjects: 87
Study 30905173 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (standard care)
Number of subjects: 87
Study 27984918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen treatment for AUD
Number of subjects: 792
Study 26670916 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Kinesiotherapy (G2)
Number of subjects: 48
Study 26670916 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (G1)
Number of subjects: 48
Study 26670916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 48
Study 25109850 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF
Number of subjects: 178
Study 25109850 — intervention group
Group type: COMPARATOR
Intervention: non-rhG-CSF
Number of subjects: 178
Study 22974536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1000
Study 22974536 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically guided strategy (prasugrel for *2 allele carriers, clopidogrel for non-carriers)
Number of subjects: 1000
Study 22974536 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically guided strategy for Maoris
Number of subjects: 1000
Study 22974536 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically guided strategy for Pacific Islanders
Number of subjects: 1000
Study 22974536 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1000
Study 22974536 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically guided strategy under clinical trial event rate scenario
Number of subjects: 1000
Study 19614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 2 mg/cm²
Number of subjects: 40
Study 19614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 1.5 mg/cm²
Number of subjects: 40
Study 19614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 1.0 mg/cm²
Number of subjects: 40
Study 19614894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied at 0.5 mg/cm²
Number of subjects: 40
Study 17885859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 micro g
Number of subjects: 808
Study 17885859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 micro g
Number of subjects: 808
Study 17885859 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 88 micro g
Number of subjects: 808
Study 15233397 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (FO) 1.3 g/d long-chain n-3 FA (n-3 LCPUFA)
Number of subjects: 97
Study 15233397 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (FO)
Number of subjects: 97
Study 15233397 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 97
Study 11239740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg) with positive expectancy
Number of subjects: 83
Study 11239740 — intervention group
Group type: COMPARATOR
Intervention: Placebo with positive expectancy
Number of subjects: 83
Study 11239740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg) with neutral expectancy
Number of subjects: 83
Study 11239740 — intervention group
Group type: COMPARATOR
Intervention: Placebo with neutral expectancy
Number of subjects: 83
Study 11239740 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of tramadol with positive expectancy vs neutral expectancy
Number of subjects: 83
Study 10216807 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Number of subjects: 528
Study 10216807 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg o.d. to 20 mg o.d.)
Number of subjects: 528
Study 10216807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 528
Study 8770795 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex-Foot
Number of subjects: 7
Study 8770795 — intervention group
Group type: COMPARATOR
Intervention: SACH, Flex-Foot, Carbon Copy II, Seattle, Quantum
Number of subjects: 7
Study 8770795 — intervention group
Group type: EXPERIMENTAL
Intervention: All prosthetic feet
Number of subjects: 7
Study 2195425 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy
Number of subjects: 0
Study 2195425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 677981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 677981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31960702 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism training interventions
Number of subjects: 140
Study 31503408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using bi-directional texting platform for home BP measurements.
Number of subjects: 0
Study 31503408 — intervention group
Group type: COMPARATOR
Intervention: Control group using standard practice for home BP measurement reporting.
Number of subjects: 0
Study 31503408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 0
Study 27507191 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms (upper quartile)
Number of subjects: 2802
Study 27507191 — intervention group
Group type: COMPARATOR
Intervention: Lower anxiety symptoms (bottom quartile)
Number of subjects: 2802
Study 26354212 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive care awareness campaign
Number of subjects: 600
Study 26354212 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-campaign)
Number of subjects: 600
Study 26354212 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation to community-based health insurance (CBHI)
Number of subjects: 600
Study 24014985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine hydrochloride
Number of subjects: 295
Study 24014985 — intervention group
Group type: COMPARATOR
Intervention: 0.5% intracameral preservative free xylocaine
Number of subjects: 295
Study 24014985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 295
Study 21074576 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberating moral dilemmas during the IGT
Number of subjects: 0
Study 21074576 — intervention group
Group type: EXPERIMENTAL
Intervention: Smelling novel aromas during the IGT
Number of subjects: 0
Study 20005820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 hr of intensive remedial instruction
Number of subjects: 0
Study 17517295 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with anorganic bovine bone and resorbable collagen membrane
Number of subjects: 44
Study 17517295 — intervention group
Group type: COMPARATOR
Intervention: No graft or membrane (Control)
Number of subjects: 44
Study 16091239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (CART)
Number of subjects: 0
Study 16091239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence interventions that are multifaceted, flexible, and protracted
Number of subjects: 0
Study 16091239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence programs
Number of subjects: 0
Study 11606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover (electric)
Number of subjects: 33
Study 11606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips‐Jordan HP 510 (electric)
Number of subjects: 33
Study 11606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactona orthodontic toothbrush (manual)
Number of subjects: 33
Study 11606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B Advantage Control Grip (manual)
Number of subjects: 33
Study 9586617 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 14
Study 9586617 — intervention group
Group type: COMPARATOR
Intervention: Control saline
Number of subjects: 14
Study 7925882 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide (100 micrograms)
Number of subjects: 9
Study 7925882 — intervention group
Group type: COMPARATOR
Intervention: Histamine (40 micrograms.ml‐1)
Number of subjects: 9
Study 2681438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis for Pneumocystis carinii pneumonia
Number of subjects: 0
Study 2681438 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction followed by maintenance therapy
Number of subjects: 0
Study 378452 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 1 gm intravenously at the start of cardiopulmonary bypass and another gram during the procedure
Number of subjects: 50
Study 378452 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 50
Study 378452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31959014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500-mg sodium meals
Number of subjects: 27
Study 31959014 — intervention group
Group type: COMPARATOR
Intervention: 3000-mg sodium meals
Number of subjects: 27
Study 30949747 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: medical air-pure oxygen-carbogen
Number of subjects: 8
Study 30949747 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: medical air-carbogen-pure oxygen
Number of subjects: 8
Study 28505199 — intervention group
Group type: EXPERIMENTAL
Intervention: Incoming emergency call shift
Number of subjects: 22
Study 28505199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatch shift
Number of subjects: 22
Study 28505199 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐assessment shift
Number of subjects: 22
Study 28505199 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 22
Study 25466837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (cooling to 32‐34°C for 24 hours)
Number of subjects: 100
Study 25466837 — intervention group
Group type: COMPARATOR
Intervention: Control (uncontrolled temperature)
Number of subjects: 100
Study 23611332 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cup group (BC group) - wore breast cups for at least 8 hours during the daytime
Number of subjects: 90
Study 23611332 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cup group (BC group)
Number of subjects: 90
Study 23611332 — intervention group
Group type: COMPARATOR
Intervention: Expectant group (EX group) - did not use breast cups
Number of subjects: 90
Study 16719605 — intervention group
Group type: EXPERIMENTAL
Intervention: Three levels of physical activity intervention
Number of subjects: 874
Study 15707545 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched counseling from family physician and dietitian
Number of subjects: 143
Study 15707545 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study 10806285 — intervention group
Group type: EXPERIMENTAL
Intervention: Black female patient (actor)
Number of subjects: 164
Study 10806285 — intervention group
Group type: COMPARATOR
Intervention: White male patient (actor)
Number of subjects: 164
Study 8787428 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (oral anticoagulation)
Number of subjects: 45
Study 1439693 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified EVA‐System with total amplitude reduced to 0.4 mm and a highly flexible file (Cavishape, grain 25 microns)
Number of subjects: 81
Study 1439693 — intervention group
Group type: COMPARATOR
Intervention: Axial margin trimmer
Number of subjects: 81
Study 6383839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg p.o. q 6 hr X 4) and fluphenazine (2.5 mg p.o. q 6 hr X 4)
Number of subjects: 51
Study 6383839 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (20 mg q 6 hr X 4)
Number of subjects: 51
Study 6383839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline plus fluphenazine (AF)
Number of subjects: 51
Study 6383839 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (M)
Number of subjects: 51
Study 30740895 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3662 (11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor)
Number of subjects: 0
Study 29068578 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h)
Number of subjects: 90
Study 29068578 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + 6% desflurane inhalation for 15 min before and after cross-clamping
Number of subjects: 90
Study 29068578 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (2‐3 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + continuous 6% desflurane inhalation
Number of subjects: 90
Study 29068578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 90
Study 26636506 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive manipulative reduction with poking k-wire fixation
Number of subjects: 96
Study 26636506 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (plate group)
Number of subjects: 96
Study 24471247 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 236
Study 24471247 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 236
Study 21536607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier + 30% sucrose
Number of subjects: 24
Study 21536607 — intervention group
Group type: COMPARATOR
Intervention: Sterile water without pacifier
Number of subjects: 24
Study 19653754 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked stop signals
Number of subjects: 0
Study 16945128 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by professional health workers (2 visits per year for 2 years)
Number of subjects: 196
Study 16945128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 196
Study 12735659 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol + fluticasone (50 microg + 250 microg)
Number of subjects: 16
Study 10709152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (3.6 to 16 mg) intranasally two or six times daily for 4 to 5 days
Number of subjects: 171
Study 10709152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir as an intranasal spray (3.4 mg/nostril), inhaled powder (10 mg), or combination of intranasal and inhaled formulations twice daily for 5 days
Number of subjects: 171
Study 8930457 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone administered preoperatively
Number of subjects: 111
Study 8930457 — intervention group
Group type: COMPARATOR
Intervention: Historical control group receiving 500 mg methylprednisolone as intraoperative bolus
Number of subjects: 111
Study 8930457 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative glucocorticosteroids
Number of subjects: 111
Study 8930457 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 111
Study 1411887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooper's ligament (McVay) repair
Number of subjects: 269
Study 1411887 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 269
Study 1411887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral inguinal hernias
Number of subjects: 269
Study 1411887 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral repairs
Number of subjects: 269
Study 4044467 — intervention group
Group type: EXPERIMENTAL
Intervention: latamoxef 6 g/day for six days
Number of subjects: 14
Study 4044467 — intervention group
Group type: EXPERIMENTAL
Intervention: latamoxef 12 g/day for four days
Number of subjects: 14
Study 4044467 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime 12 g/day for seven days
Number of subjects: 14
Study 4044467 — intervention group
Group type: COMPARATOR
Intervention: cefoperazone 6 g/day
Number of subjects: 14
Study 30246667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg oral ketamine, thrice weekly for 21 days
Number of subjects: 41
Study 30246667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29693314 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC allelic diversity and presence of particular alleles
Number of subjects: 0
Study 29693314 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC allele that impairs survival
Number of subjects: 0
Study 29693314 — intervention group
Group type: COMPARATOR
Intervention: Genetic similarity based on MHC sequences
Number of subjects: 0
Study 27191385 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone closed-loop system with simplified meal bolus strategy
Number of subjects: 12
Study 25301035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers (past and present)
Number of subjects: 193
Study 25301035 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary albumin/creatinine ratio
Number of subjects: 193
Study 25301035 — intervention group
Group type: COMPARATOR
Intervention: Overall population (type 2 diabetes patients)
Number of subjects: 193
Study 21796050 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Number of subjects: 42
Study 21796050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (A)
Number of subjects: 42
Study 21796050 — intervention group
Group type: COMPARATOR
Intervention: Combination exercise (Aerobic plus Resistance, AR)
Number of subjects: 42
Study 21796050 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercise (F)
Number of subjects: 42
Study 20157648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-out (PL) test
Number of subjects: 40
Study 20157648 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified push-out (MP) test
Number of subjects: 40
Study 20157648 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-out (PS) test
Number of subjects: 40
Study 20157648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourglass microtensile (HM) test
Number of subjects: 40
Study 17667567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0, 4.0, 8.0, 12.0, or 16.0 mg/kg)
Number of subjects: 45
Study 17667567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 45